Megan Mantica

Trials

Studies that name Megan Mantica as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:44 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT07629089 · VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations

  Megan Mantica · not yet recruiting · Recurrent Glioma, IDH-mutant Gliomas · principal investigator
• Ph1
  NCT07422363 · Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

  National Cancer Institute (NCI) · not yet recruiting · Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 Glioma · principal investigator
• Ph2
  NCT06328036 · Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

  National Cancer Institute (NCI) · withdrawn · Recurrent Glioblastoma, IDH-Wildtype · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:44 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• NCI ETCTN Pittsburgh Cancer Consortium (PCC)
  UM1CA186690 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD, Farshid Dayyani, Liza Cosca Villaruz · fiscal years 2014 to 2026
  Named on NCT07422363, NCT06328036